Entering text into the input field will update the search result below

Lannett receives FDA approval for Dronabinol Capsules

  • Lannett Company (NYSE:LCI) has received the FDA approval for its Abbreviated New Drug Application for Dronabinol Capsules USP, 2.5 mg, 5 mg and 10 mg, the therapeutic equivalent to, Marinol Capsules 2.5 mg, 5 mg and 10 mg of AbbVie Inc.
  • According to IMS, total U.S. sales of Dronabinol Capsules was ~$120M, for year ending March 31.

Recommended For You

More Trending News

Related Stocks

SymbolLast Price% Chg
LCINQ--
Lannett Company, Inc.